Ocean Biomedical, Inc. (OCEA)
| Market Cap | 209.13K -85.2% |
| Revenue (ttm) | n/a |
| Net Income | -30.72M |
| EPS | -0.71 |
| Shares Out | 232.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 300 |
| Open | 0.0002 |
| Previous Close | 0.0009 |
| Day's Range | 0.0002 - 0.0009 |
| 52-Week Range | n/a |
| Beta | 0.31 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 28, 2026 |
About Ocean Biomedical
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases in the United States. The company’s oncology product candidates include OCX-253 anti-Chi3l1 Single-target mAb and OCX-410 anti-Chi3l1/PD-1 Bi-specific antibody for the treatment of non-small cell lung cancer; and OCX-909 anti-Chi3l1/CTLA-4 Bi-specific antibody to treat glioblastoma multiforme. Its fibrosis product candidates consist of OCF-203 anti-Chit1 small molecule for the treatment o... [Read more]
Financial Performance
Financial StatementsNews
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Ocean Biomedical (OCEA), 231% surge in interest iBio (IBI...
Ocean Biomedical expands into energy, digital asset sectors
Ocean Biomedical (OCEA) announced a strategic expansion of its business operations to include power infrastructure development and a cryptocurrency treasury strategy, including Bitcoin and Solana. Thi...
Ocean Biomedical granted notice of grant on patent right by CNIPA
Ocean Biomedical (OCEA) announced that the China National Intellectual Property Administration has granted a notice of grant on patent right for its bispecific antibodies targeting CHI3L1 and PD1, des...
Ocean Biomedical announces findings in EGFR-mutant lung cancer
Ocean Biomedical (OCEA) announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy candidates to favorably interact with tyrosine kinase inhibitors, ...
Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest Providence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) today announced newly publishe...
Ocean Biomedical advances malaria vaccine research with new funding, pathway
Ocean Biomedical (OCEA) announced that its Scientific Co-founder, Dr. Jonathan Kurtis, MD, PhD, and his research team have received additional significant funding from the National Institutes of Healt...
Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development Pathway
Providence, RI, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) announced today that its Scientific Co-founder, Dr. Jonathan Kurtis, MD, PhD, and his research team have received addi...
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
PROVIDENCE, Rhode Island, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on November 18, 2024, it received a notice from The Nasdaq Stock Market LLC (“Na...
Ocean Biomedical receives noncompliance letter from Nasdaq
Ocean Biomedical (OCEA) announced that it received a letter from Nasdaq stating that on April 18, May 22 and August 19, staff notified the company that it did not comply…
Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter
PROVIDENCE, Rhode Island, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on October 16, 2024, it received a Staff Determination Letter from The Nasdaq St...
Ocean Biomedical, Molecure sign licensing agreement for YKL-40 inhibitors
Molecure has signed an exclusive licensing agreement with Ocean Biomedical. The agreement concerns the development and commercialization of the selective YKL-40 inhibitor program, including the lead m...
Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors.
This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as we...
Ocean Biomedical’s oncology platform included in new published study
Ocean Biomedical announced that Scientific Co-founder Jack A. Elias and colleagues have published new research in the Journal of Immunology that expands understanding of how CHI3L1 inhibits the body’s...
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses
Ocean Biomedical's Anti-CHI3L1 patent coverage includes multiple methods of use for targeting a broad range of Cancers that include Lung Cancer, Glioblastoma, Prostate Cancer, Melanoma, and Breast Can...
Ocean Biomedical: Dr. Jonathan Kurtis, MD issued patent for malaria treatment
Ocean Biomedical announced that its Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been issued a key U.S. patent for his groundbreaking malaria therapeutic antibody discovery that targets PfG...
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company's Malaria Treatment and Prevention Platforms
Providence, RI, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) announced today that its Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been issued a key U.S. patent for hi...
Ocean Biomedical receives noncompliance notification from Nasdaq
Ocean Biomedical announced that it received a notice from Nasdaq stating that because the company has not yet filed its quarterly report on Form 10-Q for the period ended June…
Ocean Biomedical congratulates joint venture partner Virion Therapeutics
Ocean Biomedical congratulates its JV partner Virion Therapeutics on its late breaker presentation highlighting the first-ever human immunogenicity data from its novel checkpoint modifier immunotherap...
Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024
Providence, RI, June 05, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research scienti...
Ocean Biomedical receives notice of non-compliance from Nasdaq
Ocean Biomedical received a notice from The Nasdaq Stock Market stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended March…
Ocean Biomedical announces patent allowance for Malaria antibodies
Ocean Biomedical announced that Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been granted a new patent for his malaria therapeutic antibody discoveries, targeted to both prevent malaria inf...
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease
Providence, RI, May 16, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) announced today that Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been granted a new patent for his malaria...
Ocean Biomedical receives Nasdaq notice regarding late filing
Ocean Biomedical announced that on April 18, 2024, it received a notice from The Nasdaq Stock Market LLC stating that because the Company has not yet filed its Annual Report…
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K
PROVIDENCE, Rhode Island, April 24, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on April 18, 2024, it received a notice from The Nasdaq Stock Market LLC (“Nasd...
Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL
Providence, RI, March 28, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research scient...